TheraRadar
← Back
Data updated: Jul 17, 2026

ZYDUS PHARMS

Generics
CardiovascularOncologyInfectious Disease Execution: Fair

ZYDUS PHARMS is a generic drug manufacturer focused on Cardiovascular, Oncology, Infectious Disease. Key products include ABACAVIR SULFATE AND LAMIVUDINE.

1998
Since
207
Drugs
-
Trials
4
New Drugs (2yr)
Modality:

ZYDUS PHARMS at a Glance

  • Growing R&D activity with 5 trials in last 2 years
  • Fast trial execution (32 months median completion)

ZYDUS PHARMS's Recent FDA Approvals

ZYDUS PHARMS secured 4 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

DULOXETINE HYDROCHLORIDE NDA
2026-02-27
duloxetine hydrochloride
FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.
PYRIDOSTIGMINE BROMIDE NDA
2024-10-04
pyridostigmine bromide
INDICATIONS AND USAGE Pyridostigmine Bromide Tablets USP are useful in the treatment of myasthenia gravis.
BORTEZOMIB NDA
2024-08-26
bortezomib

ZYDUS PHARMS's Therapeutic Areas

ZYDUS PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Oncology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 32%
19 drugs
Oncology 20%
12 drugs
Infectious Disease 19%
11 drugs
Neurology 17%
10 drugs
Gastroenterology 12%
7 drugs

ZYDUS PHARMS's Top Competitors

ZYDUS PHARMS's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Pfizer, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Bristol-Myers Squibb big-pharma
Oncology, Infectious Disease, Gastroenterology, Neurology
Pfizer big-pharma
Oncology, Infectious Disease, Neurology
GE HEALTHCARE specialty
Neurology, Cardiovascular, Infectious Disease, Oncology
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular
Baxter specialty
Infectious Disease, Cardiovascular, Oncology

ZYDUS PHARMS Pipeline Snapshot

Active clinical trials for ZYDUS PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • DICLOFENAC SODIUM AND MISOPROSTOL leads revenue
  • • 5 key drugs tracked

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/3 completed
  • • Speed: 32 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges